# Applied Proteomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/applied-proteomics

- Industry: Healthcare Specialists
- Headquarters: San Diego, US
- Website: www.appliedproteomics.com
- Total disclosed funding: $50M
- Latest round: Series C (Aug 20, 2013)
- Investors on record: 3

## About

Applied Proteomics focuses on innovative protein-based diagnostic tests, particularly for colorectal cancer, aiding healthcare providers in assessing patient health efficiently.Applied Proteomics, Inc. specializes in protein-based diagnostics, particularly evaluating colorectal cancer. Founded by David Agus, the company is headquartered in San Diego, US. They raised USD 2.86 mn in Series C funding on August 20, 2013, from Domain Associates and Vulcan Capital, bringing the total amount raised to USD 2.86 mn with a current company valuation of USD 127.058 mn.Applied Proteomics, Inc. offers advanced protein-based diagnostic tests, notably the SimpliPro Colon™ evaluation, a blood test that assesses colorectal wellness by analyzing 11 protein markers associated with esophageal cancer and advanced adenoma risks. This test enhances adherence to colonoscopy among symptomatic patients and serves healthcare providers, including hospitals and clinics across North America and Europe.Applied Proteomics generates revenue primarily through direct sales of the SimpliPro Colon™ evaluation to healthcare providers. Sales are conducted through contracts or partnerships, facilitating access to advanced diagnostic testing. A tiered pricing model may be employed based on the volume of tests ordered, fostering long-term relationships with clinical clients and enhancing test accessibility.Applied Proteomics plans to leverage the recent USD 2.86 mn Series C funding to further develop new diagnostic products and expand into new geographic markets. Specific future products are under design, with an emphasis on enhancing colorectal cancer diagnostics. The company aims to penetrate additional healthcare markets in North America and Europe by 2015, further solidifying its presence in the diagnostic testing industry.

## Funding rounds

- Series C, Aug 20, 2013, $2.9M — Domain Associates, Vulcan
- Series C, Feb 8, 2013, $25M — Domain Associates, Vulcan, Genting Berhad
- Series B, Feb 7, 2012, $23M — Domain Associates, Vulcan

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B, Series C
- Genting Berhad — Series C